Tonacchera M, Chiovato L, Pinchera A, Agretti P, Fiore E, Cetani F, Rocchi R, Viacava P, Miccoli P, Vitti P
Istituto di Endocrinologia, Università di Pisa, Italy.
J Clin Endocrinol Metab. 1998 Feb;83(2):492-8. doi: 10.1210/jcem.83.2.4559.
Toxic multinodular goiter is a cause of nonautoimmune hyperthyroidism and is believed to differ in its nature and pathogenesis from toxic adenoma. Gain-of-function mutations of the TSH receptor gene have been identified as a cause of toxic adenoma. The pathogenesis at the molecular level of hyperfunctioning nodules in toxic multinodular goiter has yet not been reported. Six patients with a single hot nodule within a multinodular goiter and 11 patients with toxic thyroid adenoma were enrolled in our study. At histology five hyperfunctioning nodules in multinodular goiters showed the features of adenomas, and one was identified as a hyperplastic nodule. The entire exon 10 of the TSH receptor gene was directly sequenced after PCR amplification from genomic DNA obtained from surgical specimens. Functional studies of mutated receptors were performed in COS-7 cells. Five out of 6 (83%) hyperfunctioning nodules within toxic multinodular goiters harbored a TSH receptor mutation. A TSH receptor mutation was also evident in the hyperfunctioning nodule that at histology had the features of noncapsulated hyperplastic nodule. Among toxic adenomas, 8 out of 11 (72%) nodules harbored a TSH receptor mutation. All the mutations were heterozygotic and somatic. Nonfunctioning nodules, whether adenomas or hyperplastic nodules present in association with hyperfunctioning nodules in the same multinodular goiters, had no TSH receptor mutation. All the mutations identified had constitutive activity as assessed by cAMP production after expression in COS-7 cells. Hyperfunctioning thyroid nodules in multinodular goiters recognize the same pathogenetic event (TSH receptor mutation) as toxic adenoma. Other mechanisms are implicated in the growth of nonfunctioning thyroid nodules coexistent in the same gland.
毒性多结节性甲状腺肿是非自身免疫性甲状腺功能亢进的一个病因,据信其性质和发病机制与毒性腺瘤不同。促甲状腺激素(TSH)受体基因的功能获得性突变已被确认为毒性腺瘤的一个病因。毒性多结节性甲状腺肿中功能亢进结节的分子水平发病机制尚未见报道。我们的研究纳入了6例多结节性甲状腺肿内有单个热结节的患者和11例毒性甲状腺腺瘤患者。组织学检查显示,多结节性甲状腺肿中的5个功能亢进结节具有腺瘤特征,1个被鉴定为增生性结节。从手术标本获取的基因组DNA经PCR扩增后,对TSH受体基因的整个第10外显子进行直接测序。在COS-7细胞中对突变受体进行功能研究。毒性多结节性甲状腺肿中的6个功能亢进结节中有5个(83%)存在TSH受体突变。在组织学上具有非包膜增生性结节特征的功能亢进结节中也明显存在TSH受体突变。在毒性腺瘤中,11个结节中有8个(72%)存在TSH受体突变。所有突变均为杂合性和体细胞性。无功能结节,无论是腺瘤还是与同一多结节性甲状腺肿中的功能亢进结节相关存在的增生性结节,均无TSH受体突变。通过在COS-7细胞中表达后cAMP产生评估,所有鉴定出的突变均具有组成性活性。多结节性甲状腺肿中的功能亢进甲状腺结节与毒性腺瘤具有相同的致病事件(TSH受体突变)。同一腺体中并存的无功能甲状腺结节的生长涉及其他机制。